Sherwin-Williams and Valspar Merger Delayed

Completion of the merger of US paint companies Sherwin-Williams and Valspar has been postponed from Mar. 21 to Jun. 21, 2107 because of delays related to the sale of one of Sherwin-William’s businesses that is required before regulators can clear the deal.

Sherwin-Williams has not identified the business it is trying to sell. However, the Cleveland,  Ohio-based group confirmed that the required divestment will not impact the price of $113 per share that it has agreed to pay. Under the original agreement, if regulators required Sherwin-Williams to sell assets totaling more than $650 million in annual revenues, the purchase price for Valspar would fall to $105 per share.

John Morikis, chairman, president and CEO of Sherwin-Williams, said the company is in discussions with a number of prospective buyers and it continues to move forward on the divestment of a single business that it believes would allow the Federal Trade Commission to grant approval. He commented: “We remain confident in our ability to complete the divestiture at a fair price and we look forward to unlocking the value of the combined business when the Valspar acquisition closes”.

Sherwin-Williams said the extension to June should provide enough time to complete both transactions. It expects to provide more definitive timing during its first-quarter earnings conference call scheduled for Apr. 20.

The Valspar deal is reported to be the largest acquisition in Sherwin-William’s 150-year history.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.